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1. Abstract 
Identifying accurate biomarkers of cognitive decline is essential for advancing early diagnosis and 
prevention therapies in Alzheimer’s Disease. The Alzheimer’s Disease DREAM Challenge was 
designed as a computational crowdsourced project to benchmark the current state-of-the-art in 
predicting cognitive outcomes in Alzheimer’s Disease based on high-dimensional, publicly available 
genetic and structural imaging data.  This meta-analysis failed to identify a meaningful predictor 
developed from either data modality, suggesting that alternate approaches should be considered for 
to prediction of cognitive performance. 
 
2. Background 
The Alzheimer’s Disease DREAM Challenge (http://dx.doi.org/10.7303/syn2290704) was designed to 
provide an unbiased assessment of current capabilities for estimation of cognition and prediction of 
cognitive decline using genetic and imaging data from public data resources using a crowd-sourced 
approach.  The ability to predict rate of cognitive decline – both prior to and following diagnosis – is 
essential to effective trial design for the development of therapies for Alzheimer’s Disease (AD) 
prevention and treatment.  Major collaborative efforts in the field are assessing the association of 
genetic loci with AD diagnosis and the application of structural imaging for development of early 
biomarkers of diagnosis, but the utility of these approaches to estimate cognition or predict cognitive 
decline is not well established. This project was designed under the advisement of a panel of experts 
in the field to evaluate whether these questions could be meaningfully addressed with current 
methodologies given existing public data sources.  To ensure that these questions were tested across 
a broad spectrum of the latest analytical approaches, the study was designed as a crowdsourced, 
community-based challenge in which participants were invited to address one or more of the following 
three problems: (1) The prediction of cognitive decline over time based on genetic data. (2) The 
prediction of resilience to cognitive decline in individuals with elevated amyloid burden based on 
genetic data. (3) The estimation of cognitive state based on structural magnetic resonance (MR) 
imaging data. 
 
 
3. Results 
3.1 Study design and data harmonization 
To ensure that predictors were detecting true biological variation rather than study-specific technical 
variation, this project required inclusion of data from multiple study sources.  While genetic and 
imaging data have been generated within many rich longitudinal cohorts across the field, the 
procurement and harmonization of these data sets was a non-trivial problem that required solutions to 
overcome political, ethical, and technical barriers.  For example, the generation of whole genome 
sequencing data across multiple AD cohorts within the NIH-funded AD sequencing project has 
resulted in a powerful resource for genetic analysis in the field but longitudinal information on 
cognitive traits is not readily available in those datasets.  Despite limitations on data accessibility, 
multiple relevant data sources were identified and used in this project including: the Alzheimer's 
Disease Neuroimaging Initiative (ADNI)(1), the Rush Alzheimer’s Disease Center Religious Orders 
Study(2) and Memory and Aging Project (MAP)(3) and the European AddNeuroMed(4) study, which 
is part of  InnoMed, a precursor to the Innovative Medicines Initiative.  Data selection and processing 
was performed based on data availability across these three datasets.  As such, cognition was 
defined using Mini Mental State Examination (MMSE) scores(5), genetic data was provided based on 
imputation across array-based genotype data, and structural MR imaging data was reprocessed in 
each cohort using a common processing pipeline. Genetic and imaging data was supplemented with 
a limited set of covariates including diagnosis, initial MMSE score, age at the initial examination, 
years of education, gender, and APOE haplotype.  Participants were provided with data from ADNI to 
train algorithms over a four-month period and, to ensure that participation was not limited by access 
to compute resources, they were offered use of the IBM z-Enterprise cloud to perform analyses.  The 
challenge generated significant interest with 527 individuals from around the world registered to 
participate.  A leaderboard displayed accuracy of submissions throughout the duration of the 
challenge: 1,157 submissions were made for problem 1,478 submissions for problem 2, and 434 
submissions for problem 3. Thirty-two teams submitted final results that were scored based on 
prediction/estimation of blinded outcomes within ROS/MAP for genetic predictions and AddNeuroMed 
for imaging-based estimations (Figure 1).  
 
3.2 Genetic prediction of cognitive decline 
The first challenge question assessed the ability of current methods to predict change in cognitive 
examination performance based on genetic data. High prediction accuracy would signal the potential 
for noninvasive biomarkers of cognition to have a major clinical impact on early AD diagnosis and 
prevention. Previous efforts to develop predictors of change in cognitive function have not succeeded 
in providing robust and replicable models(6-8). Genetic variation has been demonstrated to influence 
AD status: rare genetic mutations at several loci are implicated in familial forms of early-onset 
disease(9) while common variation contributes 33% to variance in sporadic AD and 22 loci have been 
implicated by large-scale genetic association analyses(10, 11). However, with the exception of the 
APOE4 haplotype, there has been little success in transforming these genetic associations into 
meaningful clinical predictions of cognitive decline. For this purpose, participants were challenged to 
predict 2-year changes in MMSE scores based on genotypes imputed from SNP array data. 
Participants trained their algorithms with 767 ADNI samples and the algorithms’ predictions were 
evaluated on a test set of 1,175 ROS/MAP samples with blinded outcome measures. The algorithm 
with the best predictive performance at the midpoint of the challenge did not contain any genetic 
features beyond APOE haplotype. Since the goal of this subchallenge was to assess genetic 
contribution to prediction of cognitive decline, this top-ranked algorithm was openly shared across 
teams as an interim baseline upon which to incorporate additional genetic predictors 
(http://dx.doi.org/10.7303/syn2838779). Eighteen teams submitted final predictions.  The majority of 
methods performed significantly better than a permutation-based random model prediction (Figure 
2a). A cluster of six methods performed significantly better than the others (including the interim 
baseline model) but were statistically indistinguishable amongst themselves (Figure 2d). Of these, the 
prediction with the best overall score (team GuanLab_umich from the University of Michigan) 
achieved a Pearson correlation of 0.382 and a Spearman correlation of 0.433 (the overall score was 
a rank-based combination of these two measures of performance; see online Supplement and 
Supplementary Methods: http://dx.doi.org/10.7303/syn3383106). However, no significant contribution 
of genetics beyond APOE haplotype to predictive performance was observed across any of the 
submissions.  Given the small sample size, no conclusions can be inferred from this analysis 
regarding the existence of genetic loci associated with cognitive decline.  Rather, these observations 
suggest that predictors of cognitive decline developed based on genetic data will not be useful within 
the clinical setting.    
 
3.3 Genetic prediction of cognitive resilience 
The second question challenged participants to identify genetic predictors that could distinguish 
individuals who exhibit resilience to AD pathology as defined by minimal change in cognitive function 
despite evidence of amyloid deposition(12, 13).  Identification of genetic signatures predictive of 
cognitive resilience would aid in the elucidation of mechanisms that may confer resilience, providing a 
powerful tool to help advance AD prevention strategies and treatment development. Eleven teams 
submitted predictions of resilience based on a training set derived from 176 ADNI subjects. 
Evaluations were made using data derived from 257 individuals from the ROS/MAP data. Despite 
using the largest such public dataset assembled to date, participants were unable to develop 
algorithms with predictive performances significantly better than random (see Figure 2b, online 
Supplement and Supplementary Methods in Synapse: http://dx.doi.org/10.7303/syn3383106). While it 
is likely that the study was underpowered due to small sample size and trait heterogeneity, this result 
suggest that information about cognitive resilience is not easily discoverable from SNP analysis.  
 
3.4 Structural imaging-based estimation of cognition 
The third question challenged participants to estimate cognitive state using structural brain image 
data (Figure 1, lower panel). Brain imaging has emerged as a powerful method for monitoring 
neurodegeneration and there is great enthusiasm in the field to make use of images for diagnosis and 
prediction. There have been many attempts in the past to correlate changes in brain shape with 
disease progression and/or diagnosis, conventionally using measures of volume for a given brain 
region(14, 15). More detailed shape measures of image features including cortical thickness, 
curvature, and depth have also been found to be relevant to a variety of neurological conditions(16). 
Participants were challenged to estimate MMSE scores based on structural brain images, or shape 
information derived from these images. Participants trained algorithms using ADNI data (N=628) and 
were evaluated using AddNeuromed data (N=182) for which they were blind to outcome measures. 
To engage as many participants as possible from both within and beyond the neuroimaging 
community, the data were provided both as raw MR images and as tables containing shape 
measures (volume, thickness, area, curvature, depth, etc.) for every labeled brain region. Thirteen 
teams submitted estimates for final evaluation and all teams performed better than a random model 
(see online Supplement and Supplementary Methods in Synapse: 
http://dx.doi.org/10.7303/syn3383106). Three teams performed significantly better than the others 
(teams GuanLab_umich from the University of Michigan, ADDT from the Karolinska Institute and 
Pythia from the University of Pennsylvania) (Figure 2c) but were statistically indistinguishable from 
one another and tied for top average rank (Figure 2e). The algorithm that generated the best absolute 
mean combined rank (Team GuanLab_umich) achieved a concordance correlation coefficient of 
0.569 and Pearson's correlation of 0.573 (the overall score was a rank-based combination of these 
two measures of performance). The most common features that contributed heavily to the MMSE 
estimates across the algorithms were hippocampal volume and entorhinal thickness, corroborating 
prior work(17-19). The top three teams also found that inclusion of shape measures of the entorhinal 
cortex (volume, curvature, surface area, travel and geodesic depth) improved overall estimation. 
Other features that contributed to predictions within the top three teams’ results included volume of 
inferior lateral ventricle and amygdala (see online Supplement and Supplementary Methods in 
Synapse: http://dx.doi.org/10.7303/syn3383106).  These results validate an established relationship 
between structural imaging data and cognition.  However, the correlative performance of these 
estimators was low suggesting that their application in the clinical setting may not be sufficient to 
inform patient care. 
 
4. Discussion 
The AD DREAM Challenge provided a formalized assessment of the ability to develop meaningful 
predictions of cognitive performance from public genetic or imaging data using contemporary state-of-
the-art predictive algorithms.  Predictive performance across all three of the subchallenges was 
modest and most methods performed roughly equivalently.  Given this uniform performance, we do 
not expect that the presented results are a failure of current modeling methodologies.  A more likely 
explanation is that the data used to address these questions were inadequate to support these tasks. 
We also note that the majority of research teams that participated in this challenge did not have 
expertise in the field of AD.  Although the few teams that did posses this knowledge did not do better 
than the others, there remains the possibility that performance would have been improved by the 
inclusion of more domain experts.  
 
  
4.1 Use of genetic information for cognitive prediction 
The modest performance observed in the subchallenges focused on genetic analysis demonstrated 
that contemporary algorithms were not able to leverage genetic signal to make useful predictions for 
cognition.   These results support the prevailing expectation that genetic variants of moderate to high 
frequency will not support viable biomarker development in AD (9-11).  Although heritability estimates 
and linkage studies have demonstrated that there is a considerable estimated genetic contribution to 
AD onset and progression (11, 20, 21), evidence both within the AD field and across other complex 
disease (22) traits has indicated that this overall genetic contribution is the aggregated compilation of 
a large number of loci with small – independent or epistatic – effects. Historically, this type of signal is 
difficult to capture in predictive models and unlikely to be useful in a diagnostic setting (23).   
Furthermore, cognition is highly influenced by a host of non-genetic factors relating to lifestyle choices 
and accumulated exposures that were not represented across all of these datasets and, in fact, are 
not fully captured in most cohorts (24-27).  Non-genetic contributions to cognitive performance may 
themselves provide an important base for successful predictions. Within the context of genetic 
analysis, the absence of these factors from models confounds the ability to detect real genetic signal 
and impacts the ability to accurately model state-specific genetic contributions. As such, future inquiry 
into the use of genetic testing for prediction of cognitive performance and AD risk assessment may be 
better served by focusing on the contribution of rare genetic variation.  Recently discovered disease-
associated rare variants have larger effect sizes than common variants and confer 2 to 5 fold greater 
risk or protection in carriers relative to the general population (28-30). Ongoing large-scale 
sequencing analyses will identify additional associated rare risk variants. In sufficient numbers, the 
aggregate prevalence would support the development of a genetic diagnostic containing a library of 
rare variants. 
  
4.2 Use of structural imaging data for cognitive estimation 
While the inexpensive and noninvasive nature of genetic testing makes this approach amenable to 
population-level disease screening, the resource-intensive nature of image-based testing is better 
positioned for careful evaluation of high-risk individuals. As such, these approaches are needed to 
provide a higher confidence estimate of cognitive performance.  Although a variety of methods 
developed within the context of this challenge were able to successfully estimate cognition, none of 
these methods were sufficiently accurate to merit clinical consideration.  These observations support 
previous work in the field (17, 19) and highlight the imperfect relationship between brain structure and 
function.  Newer imaging modalities that focus on brain function and/or pathology – such as FDG-
PET (31) or tau imaging (32)– may prove more successful for assessing cognitive dysfunction. 
  
4.3  Effective performance of meta-analysis across diverse cohorts 
A major consideration for any meta-analysis is the issue of appropriate harmonization of data across 
disparate sources.   Despite leveraging several of the most deeply phenotyped cohorts in the field, 
this challenge limited analysis to those traits that were in common across cohorts.  Although this 
approach to data harmonization is standard practice for meta-analyses (10), it greatly reduced the 
depth of the information available for modeling and influenced the selection of cognitive measures for 
use as prediction outcomes.  Because each cohort had performed a battery of study-specific tests, 
this greatly limited the ability for finer grained assessment across cognitive processes. A more 
sensible approach for future analyses may be to focus effort on more sophisticated methods to 
calibrate disparate cognitive phenotypes across cohorts (33).   Another undesirable consequence of 
the focus on traits measured in common was the inability to incorporate into model development the 
full spectrum of non-genetic and non-imaging factors that are known to influence cognitive 
performance (24-27).  This suggests the need for development of alternate approaches for integrating 
heterogeneous data and/or assessing replication across cohorts. Alternatively, smaller scale analyses 
that prioritize phenotypic depth over sample size may afford a more refined view of disease.  
 
In summary, this challenge demonstrated that predictions of cognitive performance developed from 
genetic or structural imaging data were modest across a diverse set of contemporary modeling 
methods.  Future efforts to identify clinically relevant predictors of cognition will benefit from a focus 
on alternate data sources as well as methods that work to incorporate greater phenotypic complexity.  
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FIGURE LEGENDS:  
Fig.1. Challenge overview. 
The top schematic summarizes the three challenge questions on the left column, the training data in 
the middle, and the test data on the right, including numbers of subjects. The symbols represent 
sources of data (demographic, ROS/MAP genetic, and ADNI or ANM brain images and shape 
information). The bottom panel provides example brain image labels and shape information provided 
to the participants for question 3. Anatomical labels for left cortical regions are shown on the left and 
just a couple of the cortical surface shape measures are shown on the right (travel depth on top and 
mean curvature below), for both uninflated and inflated surfaces (top and bottom rows, respectively). 
 
Figure 2.  Performance evaluation results. Panels a, b, and c report the p-values (in negative log10 
scale) for intersection union tests investigating which teams performed better than random for 
questions 1, 2, and 3, respectively. Explicitly, for question 1 (panel a) we tested the null hypothesis 
that at least one of the four correlation coefficients (namely, Pearson/clinical, Pearson/clinical + 
genetics, Spearman/clinical, Spearman/clinical + genetics) is equal to zero, against the alternative 
that all four correlation coefficients are larger than zero. Adopting a 0.05 significance level, 26 out of 
the 32 submissions were statistically better than random, after Bonferroni multiple testing correction 
for 32 tests (submissions crossing the black vertical line). For question 2 (panel b), we tested the null 
hypothesis that balanced accuracy = 0.5 or AUC = 0.5, against the alternative that balanced accuracy 
> 0.5 and AUC > 0.5. In this case, no model performed significantly better than random and, 
therefore, no best performer was declared. For question 3 (panel c), we tested the null hypothesis 
that Pearson's correlation (COR) or Lin's concordance correlation coefficient (CCC) are equal to zero, 
against the alternative that both COR and CCC are larger than zero.  Adopting a 0.05 significance 
level, all 23 submissions were statistically better than random, after Bonferroni correction. For all 
three questions, the p-values were computed from an empirical null distribution based on 10,000 
permutations.  Panels d and e report the bootstrapped assessment of ranks for questions 1 and 3, 
respectively. Samples were resampled with replacement from the original data (true outcome and 
team’s predictions), and the ranks of the different teams were re-assessed in each of 100,000 re-
samplings. Submissions were sorted according to the median of their bootstrapped average ranking 
distributions. The black horizontal line represents the posterior odds cutoff from the Bayesian 
analysis.  Teams above the black line are statistically tied to the top ranked model, according to a 
posterior odds threshold of 3. 
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